Beyond the Bolus Blog for Healthcare Providers
Let’s face it, while diabetes technologies are often offered to patients with type 1 diabetes, the same options are not always given to patients with type 2 diabetes. But the paradigm is slowly shifting.
For the first time, in 2025,
Omnipod 5 is the first automated insulin delivery system (AID) FDA cleared for patients with type 2 diabetes in the US. It is also the first and only tubeless AID system in the US. A single arm, multicenter prospective study by Pasquel et al. evaluated the safety and efficacy of the Omnipod 5
The American Diabetes Association’s (ADA) new guideline changes signify stronger recommendations for insulin pump therapies than in the past and recognize their benefits in patients with insulin-requiring type 2 diabetes (T2D).
The ADA
Categories
In February of 2024, Forlenza et al.
As clinicians, our intention is to provide quality patient care and education to people living with diabetes. However, upon diagnosis, we tend to impart a deluge of “new and critical” information all at once.
As clinicians who care for and counsel people with diabetes, we’ve become familiar with the concepts of delivering person-centered care and using shared decision-making.
The author has been compensated for this article.